Trichloroethylene

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Well, Small-cell carcinoma, Therapeutic index, Glomus tumor, Endometrial cancer, Survival, Environment, Service provider, Trichloroethylene, Patient, Primate, Triple-negative breast cancer, Lead, Zymeworks, 3D, Standard of care, Cancer, TAA, Spacecraft, Lung cancer, IND, CD3, DLL3, AACR, Workflow, Antibody, TCE, CD28, Therapy, Stomach, ADC, Vaccine

The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.

Key Points: 
  • The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.
  • An investigational new drug (IND) submission or foreign equivalent is planned for 2024.
  • Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with a poor prognosis and high unmet medical need2.
  • Displays no cross-linking of T cells and exhibits obligate cis T cell binding of CD28, requiring co-engagement of CD3.

CDR-Life Unveils Results on T-Cell Engagers Targeting Hard-to-Treat Solid Tumors at AACR 2024

Retrieved on: 
Friday, April 5, 2024
Cell, Trichloroethylene, Patient, Lung, Epitope, Breast, KK, Allele, AACR, Cancer, Antibody, TCE, Therapy, Peptide, Vaccine

Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.

Key Points: 
  • Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.
  • However, high levels of similar off-target peptides presented in healthy tissues make targeting the KK-LC-1/HLA-A*01 challenging.
  • CDR-Life’s data gathered on pMHC TCE antibodies with high specificity towards HLA-A*01 restricted KK-LC-1 epitopes demonstrate the antibodies’ promising anti-tumor activity and specificity for KK-LC-1/HLA-A*01 positive tumors.
  • In vitro studies showed significantly higher TCE-dependent T-cell activation towards cells presenting the target peptide compared to the risk peptides.

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Toxicity, 5T4, Translational research, Autoimmunity, Risk, Trichloroethylene, SVP, Cancer, Protein, CD3, Translation, AACR, Doctor of Philosophy, MHC, ABCL, TCE, Safety, CD28, San Diego Convention Center, PSMA, Peptide, Pharmaceutical industry

Together, AbCellera’s data demonstrate that it is well-positioned to advance TCEs as a drug class by widening the therapeutic window, enhancing potency, and broadening the accessible target space.

Key Points: 
  • Together, AbCellera’s data demonstrate that it is well-positioned to advance TCEs as a drug class by widening the therapeutic window, enhancing potency, and broadening the accessible target space.
  • “Our data illustrate that we can repeatedly generate TCEs that maximize tumor-cell killing without inducing excessive cytokine release.
  • The data show that AbCellera’s IgG and heavy chain-only CD28-binding antibodies do not display superagonist activity — a property associated with toxicity.
  • “We look forward to advancing these programs with the aim of delivering powerful new medicines for patients.”

VANTAGE TO HIGHLIGHT NEW iSAP™ 311 INHIBITED SURFACE ADHESION PROMOTER AT MRO AMERICAS

Retrieved on: 
Thursday, March 21, 2024
Aircraft, Tetrachloroethylene, Professional baseball, Vantage, Elastomer, Trichloroethylene, MRO, Corrosion, Plastic, TCE, PERC, FS, Dry cleaning

Deerfield, Ill., March 21, 2024 (GLOBE NEWSWIRE) -- Vantage, a global supplier of surface treatment technologies, will highlight its new iSAP 311 Inhibited Surface Adhesion Promoter as part of a complete range of cleaning solutions and surface preparation products for commercial, military and general aviation at MRO Americas (Booth 652) in Chicago, Illinois April 9 – 11, 2024.

Key Points: 
  • Deerfield, Ill., March 21, 2024 (GLOBE NEWSWIRE) -- Vantage, a global supplier of surface treatment technologies, will highlight its new iSAP 311 Inhibited Surface Adhesion Promoter as part of a complete range of cleaning solutions and surface preparation products for commercial, military and general aviation at MRO Americas (Booth 652) in Chicago, Illinois April 9 – 11, 2024.
  • Launched in 2023, its iSAP 311 Inhibited Surface Adhesion Promoter is an advanced non-chromated surface pretreatment, engineered to provide both adhesion promotion and corrosion resistance before the application of multi-layered paint system stack-ups.
  • “Our commitment to expanding our market expertise reinforces our position as technical leaders in surface treatment technologies.
  • iTPC™ 37 Remover Inhibited Temporary Protective Coating Remover – A ready to use inhibited, water-based cleaning solution formulated to remove strippable temporary protective coatings (TPCs).

Clasp Therapeutics Launches With $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers With Unparalleled Specificity

Retrieved on: 
Wednesday, March 20, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Trichloroethylene, Patient, Cancer, HLA, HHMI, Clasp, Neoplasm, Johns Hopkins University, Therapy, Immune system, Investment, Third Rock Ventures, Engineering, Vaccine

Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), launched today with $150 million in financing.

Key Points: 
  • Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), launched today with $150 million in financing.
  • The researchers’ structure-driven understanding of human leukocyte antigen (HLA)-antibody interactions enables the engineering of advanced TCEs that can precisely target common oncogenic mutations with exquisite specificity.
  • “Clasp’s proprietary technology enables immune targeting of intracellular oncogenic driver mutations to achieve durable tumor killing, even with low levels of surface presentation.
  • By binding both the T cell and the tumor cell with absolute specificity, this approach ensures immune activation against the tumor itself while sparing normal tissue, which lacks the tumor-specific mutated peptide.

Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets

Retrieved on: 
Tuesday, March 5, 2024
Trichloroethylene, Therapy, CG1, Doctor of Philosophy, TCE, MD, Immunotherapy, Monroe Dunaway Anderson, AACR, Cathepsin G, Annual general meeting, Safety, MD Anderson Cancer Center, University, Mass spectrometry, Myeloid leukemia, TCR, Malignancy, CTSG, Cancer, Pharmaceutical industry

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Crossbow Therapeutics, Inc., a biotechnology company focused on advancing T-Bolt™ therapies, a novel class of antibody therapeutics that mimic T-cell receptors (TCR-mimetics), today announced the nomination of its first development candidate, CBX-250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid leukemia.

Key Points: 
  • The oral presentation will provide an overview of the preclinical characteristics of CBX-250, which targets a cathepsin G (CTSG) peptide-human leukocyte antigen (pHLA) complex.
  • The complex is abundantly expressed on leukemic cells, but not on normal cells, allowing CBX-250 to target cancer cells efficiently while sparing normal myeloid cells.
  • “Nominating CBX-250 as a development candidate validates our initial scientific hypothesis, and it brings us a step closer to entering the clinic and ultimately helping to cure cancer,” said Briggs Morrison, Chief Executive Officer of Crossbow.
  • Working with MD Anderson’s ORBIT platform, a core component of the institution’s Therapeutics Discovery division , Dr. Molldrem led the development of a TCR-mimetic binder to the CG1 pHLA complex, which Crossbow licensed for the development of off-the-shelf cancer immunotherapies.

Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies

Retrieved on: 
Thursday, January 4, 2024
T cell, Immunotherapy, Partnership, Boehringer Ingelheim, Trichloroethylene, Research, TCR, Cancer, Patient, Potyvirus, Vaccine

INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ -- Boehringer Ingelheim and 3T Biosciences ("3T") today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies.

Key Points: 
  • INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ -- Boehringer Ingelheim and 3T Biosciences ("3T") today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies.
  • Despite the significant transformation of the cancer treatment landscape by immunotherapies, sustained remission only occurs in 15-20% of all cases of cancer.
  • This second research partnership with 3T builds on the successful completion of the initial research partnership announced last year by the two companies.
  • Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Retrieved on: 
Wednesday, November 22, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Boehringer, Trichloroethylene, Acquisition, Innovation, Ingelheim am Rhein, Potyvirus, Boehringer Ingelheim, Tissue, Cancer, Innovation Unit, Patient, Bi-specific T-cell engager, Bacteria, Immunotherapy, CHF, Pharma, Fine chemical, Vaccine, Allschwil

Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF.

Key Points: 
  • Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF.
  • T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments.
  • “The acquisition of T3 Pharma will significantly expand our immuno-oncology pipeline portfolio and is synergistic with many of our existing R&D programs.
  • Boehringer Ingelheim is adopting a comprehensive approach to cancer therapy development including both cancer cell-directed and immuno-oncology approaches.

NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
TCE, Drug resistance, ROR1, Society, Hematology, CLL, Lymphoid neoplasms with plasmablastic differentiation, PK, Risk, Abstract, MCL, MRD, Trichloroethylene, Pharmacology, Autoregulation, CRS, Safety, AR, Manchester Grand Hyatt Hotel, Patient, Toxicity, Cerebral autoregulation, Mantle cell lymphoma, Therapeutic index, Birth control, Pharmaceutical industry

LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough immunotherapies, alongside an Autoregulation platform, today announces the online publication of two abstracts submitted to the American Society of Hematology Annual meeting, to be held December 9-12, 2023 in San Diego, USA.

Key Points: 
  • “We are pleased to announce our forthcoming oral presentation on the hematological arm of the NVG-111-01 Phase I clinical study (NCT04763083).
  • Building upon these achievements, we are advancing the development of NVG-111 into solid tumor indications,” said Professor Amit Nathwani, Founder and CEO of NovalGen.
  • This mitigates adverse events but also facilitates the administration of higher doses over extended durations, thereby expanding the therapeutic index.
  • NovalGen have shown that applying AR to TCEs does not affect the potency, but significantly reduces toxicity in pre-clinical models.

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, ABCL, TCE, CD3, Therapy, Society for Immunotherapy of Cancer, Poster, SITC, Immunotherapy, Risk, Biology, Cytokine release syndrome, Trichloroethylene, Annual general meeting, Society, PSMA, Patient, Translation, Vaccine, AbCellera

AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) programs in two poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

Key Points: 
  • AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) programs in two poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.
  • The data illustrate how AbCellera is leveraging its TCE platform to discover and develop immuno-oncology therapeutics for multiple tumor targets.
  • In its first poster, AbCellera presented data demonstrating that TCE function is determined by multiple factors, including—but not limited to—CD3-binding affinity.
  • The poster included data from two of these programs targeting prostate-specific membrane antigen (PSMA) and melanoma-associated antigen 4 (MAGE-A4).